Search

Water pollution caused by oil spills at sea and industrial and daily wastewater discharges are causing serious damage to the ecological environment, not only in terms of economic losses but also in terms of human health and survival, a problem that needs to be addressed urgently. Oil/water separation is a global challenge, and while these problems are frequent, various oil/water separation strategies have been extensively investigated in recent years. The efficiency of the materials prepared is a key factor, as are the environmental friendliness and low cost of the methods and raw materials used in the experiments. This work reviews methods and materials applied in oil/water separation in recent years, including natural textile materials, metal meshes, synthetic membranes, particulate adsorbent materials, foams, sponges, aerogels, smart controllable special wettable separation materials.

Ammonia volatilization, which is one of the main ways that nitrogen gas is released from farmland, restricts promotion of the utilization of nitrogen fertilizer and contains some potential environmental risks. To investigate the general pattern of ammonia volatilization under actual paddy field conditions, we designed an indoor simulated system to measure the amount of ammonia volatilized within a single time period by controlling the pH and concentration of NH4+ (c(NH4+)) in the solution, the gas–liquid interfacial gas velocity, and the ambient temperature. In this paper, the influence of these factors, the synergistic effect on ammonia volatilization, and their quantitative relationship are discussed. We used solutions of ammonium bicarbonate (SAB) and diammonium phosphate (SDP) for the simulation experiments, and the results showed that there is a significant linear relationship between the amount of ammonia volatilization and c(NH4+). The correlation coefficients were between 0.9214 to 0.9897 and 0.8932 to 0.9904 for SAB and SDP, respectively. The quantitative relationship between temperature and pH and the influence factor (CIF) and the initial ammonia volatilization fluxes (IAVFs) was analyzed by the least-squares method, and the degrees of polynomial were one and two, respectively. The regression equations of the SAB and SDP among the amount of ammonia volatilization with the concentration of ammonium nitrogen, the temperature, and the pH were calculated by using MATLAB. Considering the effects of temperature and pH on the CIF and IAVFs under individual conditions, we used a binary cubic model to fit the relationship between temperature and pH to the CIF and IAVFs. The simulation results showed that the correlation coefficients between the CIF and IAVFs for SAB were 0.9980 and 0.9680, respectively, and the correlation coefficients were 0.9946 and 0.9708 for SDP, respectively. The quantitative equation took into account the coefficient of determination and degrees of polynomial, and the ammonia volatilization fluxes can be calculated by using these equations. [ABSTRACT FROM AUTHOR]

A novel plastic of polyvinyl acetate (PVAc) blended with starch was prepared in our research. Acrylic acid (AA) was added adequately in step of PVAc preparation as modifier, with emulsifier and initiator each occupied with 2.5 and 0.7 wt% of monomer. We used a capillary rheometer to evaluate rheological properties of PVAc and starch blends. The rheological behavior of the blends shows pseudoplastic and shear thinning. In this article, we also studied effects of AA content and temperature on viscosity. The results show that the viscosity of blends increased gradually as AA content increasing and it shows decreased as temperature increasing. The thermal behaviors of these materials were evaluated by differential scanning calorimetry and thermogravimetric analysis. The starch and AA content were considered to be the main influence factors. From the diagrams we concluded that the addition of adequate AA content could improve the compatibility and stability of the blends; however, the starch content was limited properly otherwise the stability of blends would be weakened., INTRODUCTION Acrylic acid (AA) is adopted to modify the blends, which are obtained by mixing the polyvinyl acetate (PVAc) with starch to prepare excellent-performance plastics [1], PVAc as white latex [...]

Carotid angioplasty and stenting (CAS) is an efficient therapeutic approach for carotid stenosis. However, in-stent restenosis (ISR) frequently occurs and seriously affects the therapeutic efficacy of CAS. Certain non-coding (nc)RNAs serve potential roles in ISR development and progression. Thus, the goals of the present study were to investigate novel biomarkers for ISR development and to further uncover the mechanisms underlying the progression of ISR. The expression of long ncRNA cyclin-dependent kinase inhibitor (CDKN)2B-antisense 1 (AS1) and microRNA (miR)-143-3p in patients with ISR and human carotid artery smooth muscle cells (hHCtASMCs) was analyzed using reverse transcription-quantitative PCR. A luciferase reporter assay was performed to examine the interaction between CDKN2B-AS1 and miR-143-3p. The effects of the CDKN2B/miR-143-3p axis on hHCtASMC proliferation and migration were assessed using Cell Counting Kit-8 and Transwell assays. The results indicated that serum CDKN2B-AS1 was increased and miR-143-3p was decreased in patients with ISR as compared with that in patients with no ISR (all P<0.001). CDKN2B-AS1 and miR-143-3p were identified as risk factors for ISR onset (all P<0.05) and knockdown of CDKN2B-AS1 in hHCtASMCs led to inhibited cell proliferation and migration. Furthermore, the luciferase reporter assay and expression analysis indicated that miR-143-3p is a target of CDKN2B-AS1 and may mediate the effects of CDKN2B-AS1 on hHCtASMC proliferation and migration. In conclusion, dysregulation of CDKN2B-AS1 and miR-143-3p may represent risk factors for the occurrence of ISR. The in vitro results suggested that the CDKN2B-AS1/miR-143-3p axis may regulate the proliferation and migration of hHCtASMCs, indicating its potential to be developed as a target for preventative measures and therapies for ISR. [ABSTRACT FROM AUTHOR]

Objective. Vitamin D is associated with neurological deficits in patients with cerebral infarction. This study uses machine learning to evaluate the prediction model's efficacy of the correlation between vitamin D and neurological deficit in patients with cerebral infarction. Methods. A total of 200 patients with cerebral infarction admitted to the Department of Neurology of our hospital from July 2018 to June 2019 were selected. The patients were randomly divided into a training set (n = 140) and a test set (n = 60) in a 7 : 3 ratio. The prediction model is constructed from the training set's data, and the model's prediction effect was evaluated by test set data. The area under the receiver operator characteristic curve was used to assess the prediction efficiency of models. Results. In the training set, the area under the curve (AUC) of the logistic regression model and XGBoost algorithm model was 0.727 (95% CI: 0.601~0.854) and 0.818 (95% CI: 0.734~0.934), respectively. While in the test set, the AUC of the logistic regression model and XGBoost algorithm model was 0.761 (95% CI: 0.640~0.882) and 0.786 (95% CI: 0.670~0.902), respectively. Conclusion. The prediction model of the correlation between vitamin D and neurological deficit in patients with cerebral infarction based on machine learning has a good prediction efficiency. [ABSTRACT FROM AUTHOR]

AbstractObjectiveMethodsResultsConclusionTo evaluate the effects of argatroban on the levels of Hcy, hs-CRP and FIB in patients with acute cerebral infarction (ACI).A retrospective analysis was performed on 382 patients with ACI who were hospitalized in the Department of Neurology of our hospital from January 2017 to December 2019. Among them, 158 patients received conventional treatment as the control group and 224 patients received combined treatment with argatroban as the study group. NHISS score, mRS score, Hcy, hs-CRP, FIB level, quality of life, adverse reactions were compared between the two groups after treatment. The levels of Hcy and hs-CRP in patients with different mRS scores were compared.A superior clinical efficacy of the study group was observed than the control group (p < 0.05). The study group witnessed a remarkably lower NHISS score, Hcy, hs-CRP and FIB level as compare to the control group (p < 0.05). The ADL and FMA scores in the study group were higher than those in the control group (p < 0.05). The levels of Hcy and hs-CRP in mRS 0–2 patients were lower than those in mRS 3–6 patients (p < 0.05).Argatroban in ACI patients can significantly enhance the clinical efficacy and improve the quality of life. It is closely related to the reduction of Hcy and hs-CRP levels, but the mechanism needs to be further studied. [ABSTRACT FROM AUTHOR]

Abstract: The nanocrystalline Co3O4 catalysts were prepared via wet-chemical precipitation and dry-solid-state reaction, respectively. To assess the suitability of such Co3O4 as an oxidation catalyst, CO oxidation was taken as model reaction. The best catalyst was obtained by dry grinding route calcined at 300°C, showing the 50% conversion of CO at −92°C, under a stream of normal feed gas containing moisture. Comparing the reaction rate per cobalt oxide mass unit at room temperature (ca. 1.53mmolg−1 s−1) with the Au-based catalyst in the current literature confirmed the exceptionally high activity of these new materials. The as-synthesized catalysts have been characterized by various techniques in a view of material characterization, as well as to investigate the mechanistic aspects of catalytic reactions. Examination of the surface nature of the materials by X-ray photoelectron spectra (XPS) and temperature-programmed desorption of oxygen (O2-TPD) shows that O− and lattice oxygen (O2−) are the predominant species at the oxidized surface. In addition, a close parallel between the catalytic activity and the concentration of O− oxygen species indicates that a large amount of more mobile and reactive O− species is the main reason for its enhanced CO oxidation activity. [Copyright &y& Elsevier]

Importance: Sublingual edaravone dexborneol, which can rapidly diffuse and be absorbed through the oral mucosa after sublingual exposure, is a multitarget brain cytoprotection composed of antioxidant and anti-inflammatory ingredients edaravone and dexborneol., Objective: To investigate the efficacy and safety of sublingual edaravone dexborneol on 90-day functional outcome in patients with acute ischemic stroke (AIS)., Design, Setting, and Participants: This was a double-blind, placebo-controlled, multicenter, parallel-group, phase 3 randomized clinical trial conducted from June 28, 2021, to August 10, 2022, with 90-day follow-up. Participants were recruited from 33 centers in China. Patients randomly assigned to treatment groups were aged 18 to 80 years and had a National Institutes of Health Stroke Scale score between 6 and 20, a total motor deficit score of the upper and lower limbs of 2 or greater, a clinically diagnosed AIS symptom within 48 hours, and a modified Rankin Scale (mRS) score of 1 or less before stroke. Patients who did not meet the eligibility criteria or declined to participate were excluded., Intervention: Patients were assigned, in a 1:1 ratio, to receive sublingual edaravone dexborneol (edaravone, 30 mg; dexborneol, 6 mg) or placebo (edaravone, 0 mg; dexborneol, 60 μg) twice daily for 14 days and were followed up until 90 days., Main Outcomes and Measures: The primary efficacy outcome was the proportion of patients with mRS score of 1 or less on day 90 after randomization., Results: Of 956 patients, 42 were excluded. A total of 914 patients (median [IQR] age, 64.0 [56.0-70.0] years; 608 male [66.5%]) were randomly allocated to the edaravone dexborneol group (450 [49.2%]) or placebo group (464 [50.8%]). The edaravone dexborneol group showed a significantly higher proportion of patients experiencing good functional outcomes on day 90 after randomization compared with the placebo group (290 [64.4%] vs 254 [54.7%]; risk difference, 9.70%; 95% CI, 3.37%-16.03%; odds ratio, 1.50; 95% CI, 1.15-1.95, P = .003). The rate of adverse events was similar between the 2 groups (89.8% [405 of 450] vs 90.1% [418 of 464])., Conclusion and Relevance: Among patients with AIS within 48 hours, sublingual edaravone dexborneol could improve the proportion of those achieving a favorable functional outcome at 90 days compared with placebo., Trial Registration: ClinicalTrials.gov Identifier: NCT04950920.

Protection roles of serum vitamin D levels in the cardiovascular system. This observational study enrolled 286 young ACI patients with type 2 diabetes mellitus in our Hospital from October 2016 to April 2020 as the study group. 127 healthy individuals as the control group. Serum levels of vitamin D and blood pressure indexes of the two groups were measured and the correlation between vitamin D levels and the clinical phenotype of young cerebral infarction was explored. Significantly higher 25-hydroxyvitamin D was observed in the study group vs. control group. During the day, The values of systolic and diastolic blood pressure and mean blood pressure was well-balanced between the two groups. However, at night and within 24 hours, significant differences in systolic and diastolic blood pressure and mean value were observed between the two groups. The higher the vitamin D level, the greater the decrease in blood pressure at night. Serum 25-hydroxyvitamin D was positively correlated with the reduction of night systolic and diastolic blood pressure. Low levels of 25-hydroxyvitamin D led to a small decrease in blood pressure at night, resulting in a vulnerable cardiovascular system and an increased incidence of cerebral infarction in the young population.

Carotid angioplasty and stenting have developed into reliable options for patients with carotid stenosis. However, postoperative restenosis remains a serious and unresolved problem. Restenosis is partly caused by the proliferation of vascular smooth muscle cells. As certain long non-coding RNAs (lncRNAs) affect cell proliferation and migration, the present study aimed to investigate them as novel biomarkers for restenosis development and to further reveal the potential underlying mechanisms. The expression of lncRNA small nucleolar RNA host gene 1 (SNHG1) and microRNA145 (miR-145) in human carotid artery smooth muscle cells (hHCtASMCs) was analyzed using reverse transcription-quantitative PCR. In addition, a luciferase reporter assay was performed to investigate the interaction between SNHG1 and miR-145. The effects of the SNHG1/miR-145 axis on the proliferation and migration of hHCtASMCs were evaluated by Cell Counting Kit-8 and Transwell assays. Serum SNHG1 and miR-145 expression levels were increased and decreased, respectively, in patients with restenosis (all P<0.001). High SNHG1 and low miR-145 were identified as risk factors for restenosis onset (all P<0.01). Furthermore, decreasing SNHG1 expression levels in hHCtASMCs inhibited cell proliferation and migration. The luciferase reporter assay and expression results demonstrated that miR-145 may be a target of SNHG1 and mediated the effects of SNHG1 on hHCtASMC proliferation and migration. The results obtained suggested that abnormal expression of SNHG1 and miR-145 may be risk factors for restenosis. The present study revealed that the SNHG1/miR-145 axis regulates hHCtASMC proliferation and migration, indicating its potential for restenosis prevention and treatment., Competing Interests: The authors declare that they have no competing interests., (Copyright: © Ma et al.)

Objective: To determine the risk factors for cognitive impairment (CI) in patients with first-time ischemic stroke., Methods: The clinical data of 180 patients with ischemic stroke who were admitted to our hospital from January 2018 to December 2019 was retrospectively analyzed. Patients with MMSE score ≤24 were included into the CI group and the rest of the patients were placed into the normal group. Multivariate logistic regression was applied to describe risk factors for CI in patients with first-time ischemic stroke., Results: Among the patients with first-time ischemic stroke, 96 cases (53%) developed CI, 84 cases (47%) were normal. In different subtypes of TOAST classifications, patients with large-artery atherosclerosis had the highest CI incidence (66.96%). For different infarction sites, the highest CI incidence occurred in the frontal lobe (82.35%), and the lowest was from cerebellar infarction (37.50%). The difference of CI incidences in the frontal lobe, parietal lobe, temporal lobe and occipital lobe was significant between the two groups (P<0.05). Logistic regression analysis indicated that independent risk factors for CI in patients with first ischemic stroke include age ≥60 years old, diabetes history, CRP >6.53 mg/L, Hcy >13.84 μmol/L, NIHSS score >4.37, VD <45.16 nmol/L, and the difference was statistically significant ( P <0.05)., Conclusion: The study showed a high CI incidence in patients with preexisting ischemic stroke. Age ≥60 years old, history of diabetes mellitus, CRP >6.53 mg/L, Hcy >13.84 μmol/L, NIHSS score >4.37 score, VD <45.16 nmol/L are independent risk factors for CI in patients with first-time ischemic stroke., Competing Interests: None., (AJTR Copyright © 2021.)

Background and Purpose: Edaravone dexborneol, comprised of 2 active ingredients, edaravone and (+)-borneol, has been developed as a novel neuroprotective agent with synergistic effects of antioxidant and anti-inflammatory in animal models. The present clinical trial aimed at testing the effects of edaravone dexborneol versus edaravone on 90-day functional outcome in patients with acute ischemic stroke (AIS)., Methods: A multicenter, randomized, double-blind, comparative, phase III clinical trial was conducted at 48 hospitals in China between May 2015 and December 2016. Inclusion criteria included patients diagnosed as AIS, 35 to 80 years of age, National Institutes of Health Stroke Scale Score between 4 and 24, and within 48 hours of AIS onset. AIS patients were randomized in 1:1 ratio into 2 treatment arms: 14-day infusion of edaravone dexborneol or edaravone injection. The primary end point was the proportion of patients with modified Rankin Scale score ≤1 on day 90 after randomization., Results: One thousand one hundred sixty-five AIS patients were randomly allocated to the edaravone dexborneol group (n=585) or the edaravone group (n=580). The edaravone dexborneol group showed significantly higher proportion of patients experiencing good functional outcomes on day 90 after randomization, compared with the edaravone group (modified Rankin Scale score ≤1, 67.18% versus 58.97%; odds ratio, 1.42 [95% CI, 1.12-1.81]; P =0.004). The prespecified subgroup analyses indicated that a greater benefit was observed in female patients than their male counterparts (2.26, 1.49-3.43 versus 1.14, 0.85-1.52)., Conclusions: When edaravone dexborneol versus edaravone was administered within 48 hours after AIS, 90-day good functional outcomes favored the edaravone dexborneol group, especially in female patients. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02430350.